The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2023 - Chicago | FGFR2b: a novel biomarker for patients with gastroesophageal cancer
Nataliya Uboha, MD, PhD, UW Carbone Cancer Center, Madison, WI, talks on FGFR2b and its possible role as a biomarker for patients with gastroesophageal cancer. Approximately 25% of patients with gastroesophageal cancer have an over-expression of FGFR2b, and the FGFR2b-targeted monoclonal antibody bemarituzumab is currently under investigation in this setting. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
